Recent advances include initial models of origins and evolution of lethal prostate cancer, simulation of personalized cancer medicine with insights into evolution and liquid biopsy, subclone eradication and resistance to current therapy, identification of extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in prostate cancer, and improved methods for obtaining high quality histology and molecular data from whole mount processed prostate tissues.